Abstract
Background: Diabetic retinopathy (DR) is the most common microvascular complication of diabetes, and is the leading cause of blindness and visual impairment in the working-age population. Retinal neovascularization is the most important clinical features of proliferative DR (PDR). Apelin is an endogenous ligand of the G proteincoupled receptor, which has been shown to be involved in retinal angiogenesis. Objective: To study vitreous and serum levels of apelin in type 2 diabetic patients with diabetic retinopathy. Patients and methods: Case control study was conducted on total 60 subjects, 40 type 2 diabetic patients and 20 non diabetic subjects as control group. Diabetic patients were divided into 2 groups. Results: Serum and vitreous levels of apelin were significantly higher in patients with PDR compared to NPDR and control group (P 4.45 ng/ml (P 3.55 ng/ml for detection of NPDR compared to control group. Conclusion: Elevation of serum apelin in patients with PDR compared to NPDR and control group suggesting the role of apelin in development of retinal neovascularization and diabetic retinopathy. So antagonizing effect of apelin can be used as targeted therapy for treatment of diabetic retinopathy. We can rely on serum apelin for early detection of diabetic retinopathy than vitreous apelin.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.